Healthcare / BiotechnologyNasdaqGS
$4.50
+0.16 (+3.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-56.0M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$629M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-63.0%
↓Gross Margin
6.9%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-603.4%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.8M · net income $-64.9M · FCF $-47.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $7.8M | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M | $6.5M | $4.2M | $6.2M | $1.7M | — | — | — | — |
| Net Income | $-64.9M | $-64.9M | $-132.1M | $-88.5M | $-86.9M | $-90.9M | $-51.0M | $-161.4M | $-132.7M | $-68.5M | $-48.1M | $-20.6M | $-8.5M | $-5.2M |
| EBITDA | $-73.6M | $-73.6M | $-51.7M | $-115.5M | $-84.4M | $-88.8M | $-49.6M | $-104.6M | $-82.9M | $-54.0M | $-48.4M | $-20.6M | — | — |
| EPS | — | — | -1.71 | -1.27 | -1.33 | -1.60 | -1.20 | -3.90 | — | — | — | — | — | — |
| Gross Margin | 6.9% | 6.9% | 17.4% | 42.1% | 59.8% | — | — | — | 52.7% | 28.3% | — | — | — | — |
| Operating Margin | -946.5% | -946.5% | -280.6% | -372.2% | -286.2% | -1327.1% | -785.4% | -2627.3% | -1378.3% | -3230.0% | — | — | — | — |
| Net Margin | -829.6% | -829.6% | -705.5% | -283.1% | -292.1% | -1344.0% | -787.0% | -3817.2% | -2158.0% | -4071.5% | — | — | — | — |
| Balance Sheet | ||||||||||||||
| Debt/Equity | — | — | — | 0.00 | 0.00 | — | 0.28 | — | 0.14 | — | — | — | — | — |
| Current Ratio | 4.03 | 4.03 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-47.2M | $-47.2M | $-56.0M | $-79.6M | $-68.2M | $-52.4M | $-39.1M | $-98.1M | $-102.2M | $-55.9M | $-34.8M | $-20.9M | — | — |
| Returns | ||||||||||||||
| ROE | -63.0% | -63.0% | -84.9% | -56.3% | -44.0% | -46.0% | -135.5% | -230.8% | -61.7% | -30.4% | -28.4% | -22.2% | 41.0% | 57.1% |
| Valuation | ||||||||||||||
| P/B | 5.27 | 5.27 | 1.29 | 0.47 | 5.46 | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| Revenue Growth | -58.2% | -58.2% | -40.1% | 5.0% | — | 4.3% | 53.3% | -31.3% | 265.5% | — | — | — | — | — |
| EPS Growth | — | — | -34.6% | 4.5% | — | -33.3% | 69.2% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+212.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.71 → n/d
Residual
+212.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.